On June 18, 2019, HRSA issued an information collection request (ICR) regarding the guidelines for manufacturer audits of 340B covered entities and the OPA informal
You will probably recall that Powers asked the HRSA HIV/HIV/AIDS Bureau (HAB) for guidance recently on whether Ryan White program income may be used to
On January 7, California Gov. Gavin Newsom signed an executive order instructing Medi-Cal to transition all pharmacy services for Medi-Cal managed care to fee-for-service (FFS)
OPA recently posted a program update entitled “Best Practices for Covered Entities: Resolving Contract Pharmacy Related Non-Compliance.” In the update, OPA states that it has
On April 30, 2018, the White House Office of Management and Budget (OMB) published a notice that HHS has withdrawn a proposed rule that would
The 340B Ceiling Price and Manufacturer Civil Monetary Penalties (CMP) rule may be a delayed a fifth time. On March 27, 2018, HRSA sent to
RWC-340B joined the 340B Coalition in submitting comments to the Health Resources and Services Administration opposing the additional delay of the 340B Ceiling Price and
The Department of Health and Human Services’ Office of the Inspector General (OIG) recently issued a report on drug supply chain security with implications for
On July 13, the Centers for Medicare and Medicaid Services, or CMS, released a proposal to reduce Medicare reimbursement for separately payable 340B drugs administered in hospitals from ASP + 6% to ASP – 22.5%. Although this proposed regulation would not affect reimbursement to Ryan White clinics, it
The Health Resources and Services Administration (HRSA) released its long-awaited 340B program omnibus guidance, often called the “Mega-Guidance” today. RWC-340B has reviewed the Mega-Guidance and is
